Appili Therapeutics, Inc. is a pharmaceutical company, which acquires and develops novel treatments targeting unmet needs in infectious disease. It focuses on building and advancing a diverse portfolio of anti-infective programs such as ATI-1501, ATI-1503, and ATI-1701. The company was founded on May 7, 2015 and is headquartered in Halifax, Canada.
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data